Objective To investigate the clinical efficacy and safety evaluation of Xipayimaizibizi liquid combined with doxazosin tablets in the treatment of chronic prostatitis.Methods 120 cases of chronic prostatis were randomly divided into control group (n =60)and treatment group (n =60)according to the random number table.The control group received doxazosin tablets and the treatment group used the doxazosin tablets combined with xipayimaizibizi liquid,and both group were treated for four weeks contin-ually.The total efficiency of the treatment of the two groups were compared.The clinical data of chronic prostatic symptom score index table (NIH-CPSI)scores,prostatic fluid white blood cell(WBC)numbers, maximal urinary flow rate and average urinary flow rate before and after treatment in both groups were ob-tained and recorded their adverse reactions.Results The efficiency of treatment group(88.33%)was sig-nificantly higher than that of the control group (61.67%)and the difference was statistically significant (P<0.05)after the course of treatments.After treatment the NIH-CPSI score was obviously lower than that before the treatment in each group.Urination scores,pain scores,quality of life scores and NIH-CPSI total scores of treatment group were significantly lower than control group,and differences were statistically sig-nificant (P <0.05).WBC counts after treatment were lower than before treatment in both groups,and WBC counts significant lower in treatment group compared with the control group after the course of treat-ment,and there was a statistical difference (P <0.05).After therapy,the maximum flow rate and average flow rate were higher than before treatment in both groups,and the maximum flow rate and average flow rate in the treatment group were obviously higher than those of the control group after the course of treat-ment with a significant difference (P <0.05).Both groups had no obvious adverse reactions.Conclusion Xipayimaizibizi liquid combined with doxazosin tablets has significant clinical effect on chronic prostatitis and has no obvious adverse reactions.The clinical application is safety and reliability and has important re-search value.%目的：探讨西帕依麦孜彼子口服液联合甲磺酸多沙唑嗪缓释片治疗慢性前列腺炎的临床疗效及安全性。方法将120例慢性前列腺炎患者随机分为对照组和治疗组，对照组（n ＝60）单用甲磺酸多沙唑嗪缓释片口服治疗，治疗组（n ＝60）予以口服甲磺酸多沙唑嗪缓释片并联合西帕依麦孜彼子口服液进行治疗，连续口服4 w。比较两组患者治疗总有效率，观察两组患者治疗前后美国国立卫生研究院慢性前列腺炎症状评分（NIH-CPSI）相关指标变化、治疗前后前列腺液白细胞（WBC）数目变化、最大尿流率及平均尿流率变化，并记录不良反应的发生情况。结果治疗组总有效率（88．33％）显著高于对照组总有效率（61．67％），差异有统计学意义（P ＜0．05）。两组患者治疗后的 NIH-CPSI 评分均优于治疗前，其中治疗组疼痛症状、排尿症状、生活质量评分及总评分均低于对照组，差异有统计学意义（P ＜0．05）。两组治疗后 WBC 计数均低于其治疗前 WBC 计数，治疗组治疗后 WBC 计数明显低于对照组治疗后 WBC 计数，差异有统计学意义（P ＜0．05）。两组患者治疗后最大尿流率及平均尿流率均明显高于治疗前，治疗组治疗后最大尿流率及平均尿流率显著高于对照组治疗后，差异均有统计学意义（P ＜0．05）。两组患者均未出现明显药物不良反应。结论西帕依麦孜彼子口服液联合多沙唑嗪片联合治疗慢性前列腺炎临床疗效显著，无明显不良反应，临床上应用可靠安全，具有重要的临床研究价值。
展开▼
